Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
262
-
Total 13F shares, excl. options
-
48.4M
-
Shares change
-
+1.58M
-
Total reported value, excl. options
-
$7.57B
-
Value change
-
+$240M
-
Put/Call ratio
-
0.98
-
Number of buys
-
156
-
Number of sells
-
-99
-
Price
-
$156.53
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q2 2018
308 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q2 2018.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 262 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.4M shares
of 62.7M outstanding shares and own 77.25% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (7.63M shares), FMR LLC (6.98M shares), VANGUARD GROUP INC (3.82M shares), BlackRock Inc. (2.79M shares), WELLINGTON MANAGEMENT GROUP LLP (1.98M shares), OppenheimerFunds, Inc. (1.6M shares), Bank of New York Mellon Corp (1.56M shares), BB BIOTECH AG (1.07M shares), STATE STREET CORP (997K shares), and JPMORGAN CHASE & CO (933K shares).
This table shows the top 262 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.